(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
the Wild in Style: The Reduced Portage Mustang's Bold Heritage - 2Investigation reveals sperm donor passed on cancer risk to dozens of children across Europe
- 3Figure out How to Streamline Your Profits in Gold Speculation
- 4Figure out How to Pick a Crematorium: Key Contemplations.
- 5Guinea-Bissau's coup called a 'sham' by West African political figures
- the 6 Shrewd Beds for seniors: A Complete Survey
- Firefighters rescue two Israelis trapped in vehicles on flooded roads in West Bank
- Grasping Wrongdoings and Crimes: A Correlation
- Miss 'Stranger Things' already? Here's how you can get your Upside Down fix in 2026 with spinoffs, games and more
- Best Streaming Gadget for Your Home Theater
- What's inside Mexico's Popocatépetl? Scientists obtain first 3D images of the whole volcano
- Kendall Jenner addresses long-standing rumor about her sexuality
- The Best Games On the planet
- Step by step instructions to Guarantee Your Internet Promoting Degree Supplements Your Profession Objectives
